Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.
An article from
Emerging biotech
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selective than — Rhythm Pharmaceuticals’ Imcivree.
Published Sept. 3, 2026
In this illustration, extracellular dopamine binds to a dopamine receptor, activating a G protein
Superluminal Medicines raises $60M Series B for Phase 1 trials of MC4R obesity drug, backed by investors including Eli Lilly, RA…
The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.
Isomorphic Labs is developing a new engine for AI drug discovery
A 'quintuple agonist,' Alector halts it Alzheimer's trial, and more biotech news from The Readout
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
Could a new class of drugs being used to treat rare neurological disorders allow people to function without sleep?
